US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MetaVia Inc

0.9173

-0.1427-13.46%

Post-market: 0.96990.0526+5.73%19:44 EDT

Volume:847.49K

Turnover:833.79K

Market Cap:22.20M

PE:-0.57

High:1.07

Open:1.05

Low:0.9173

Close:1.06

52wk High:3.72

52wk Low:0.5555

Shares:24.20M

Float Shares:9.22M

Volume Ratio:0.04

T/O Rate:9.19%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6069

EPS(LYR):-3.5570

ROE:-129.46%

ROA:-53.04%

PB:2.31

PE(LYR):-0.26

Loading ...

Overview Company News Filings

Metavia Inc. Conducted Virtual Annual Stockholders Meeting

MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session

Metavia Inc. CFO Marshall H. Woodworth Reports Acquisition of Common Shares

Metavia Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price

Metavia Inc. Unveils Presentation on Innovative Cardiometabolic Therapies Targeting Obesity and MASH

Dong-A ST Co., Ltd Acquires Common Shares of Metavia Inc

MetaVia Is Maintained at Buy by Maxim Group

MetaVia Inc reports results for the quarter ended March 31 - Earnings Summary

MetaVia Q1 EPS $(0.36) Beats $(0.51) Estimate

Metavia Inc. Reports Q1 2025 Results: Net Loss Narrows to $3.7 Million, EPS Improves to $0.36 per Share

MetaVia Inc. Announces $10 Million At-The-Market Private Placement to Fund Clinical Development

BRIEF-Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules

MetaVia Inc expected to post a loss of 60 cents a share - Earnings Preview

BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MTVA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":0.9173,"timestamp":1758225600000,"preClose":1.06,"halted":0,"volume":847492,"hourTrading":{"tag":"盘后","latestPrice":0.9699,"preClose":0.9173,"latestTime":"19:44 EDT","volume":41325,"amount":38999.041349,"timestamp":1758239085462},"delay":0,"floatShares":9219300,"shares":24197809,"eps":-1.606876,"marketStatus":"Closed","change":-0.1427,"latestTime":"09-18 16:00:00 EDT","open":1.05,"high":1.07,"low":0.9173,"amount":833789.4103472,"amplitude":0.144057,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.606876,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1758268800000},"marketStatusCode":5,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.06,"preHourTrading":{"tag":"盘前","latestPrice":1.06,"preClose":1.06,"latestTime":"09:29 EDT","volume":24273,"amount":25385.4194535,"timestamp":1758202167844},"postHourTrading":{"tag":"盘后","latestPrice":0.9699,"preClose":0.9173,"latestTime":"19:44 EDT","volume":41325,"amount":38999.041349,"timestamp":1758239085462},"volumeRatio":0.043435},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":9219300,"roa":"-53.04%","roe":"-129.46%","lyrEps":-3.556986,"volumeRatio":0.043435,"shares":24197809,"dividePrice":0,"high":1.07,"amplitude":0.144057,"preClose":1.06,"low":0.9173,"week52Low":0.5555,"pbRate":"2.31","week52High":3.7196,"institutionHeld":0,"latestPrice":0.9173,"eps":-1.606876,"divideRate":0,"volume":847492,"delay":0,"ttmEps":-1.606876,"open":1.05,"prevYearClose":2.03,"prevWeekClose":0.6959,"prevMonthClose":0.6342,"prevQuarterClose":0.6432,"fiveDayClose":0.6837,"twentyDayClose":0.6201,"sixtyDayClose":0.6714},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-07","symbol":"MTVA","fiscalQuarterEnding":"2025/06","expectedEps":-0.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-05-14","symbol":"MTVA","fiscalQuarterEnding":"2025/03","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.36},{"date":"2025-03-20","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742457600000,"name":null,"time":"Pre-Market","dateTimestamp":1742443200000,"actualEps":null},{"market":"US","date":"2024-11-07","symbol":"MTVA","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.55},{"market":"US","date":"2024-08-14","symbol":"MTVA","fiscalQuarterEnding":"2024/06","expectedEps":-1.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-1.85}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2025-09-17","current":-1.740473,"percent":0.005076,"low":-1.962939,"twenty":-0.693792,"median":-0.540029,"eighty":-0.459802,"high":-0.203888,"avg":-0.561086,"sd":0.217348,"marketCap":32183085},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270},{"date":"2025-04-25","current":-0.266622,"twenty":-0.631917,"median":-0.512617,"eighty":-0.463425,"marketCap":7356638},{"date":"2025-05-02","current":-0.239019,"twenty":-0.626947,"median":-0.506404,"eighty":-0.454331,"marketCap":6595010},{"date":"2025-05-09","current":-0.222708,"twenty":-0.618869,"median":-0.49874,"eighty":-0.452346,"marketCap":6144956},{"date":"2025-05-16","current":-0.238257,"twenty":-0.615141,"median":-0.497083,"eighty":-0.429105,"marketCap":5848960},{"date":"2025-05-23","current":-0.285534,"twenty":-0.611413,"median":-0.49458,"eighty":-0.263184,"marketCap":7009578},{"date":"2025-05-30","current":-0.543676,"twenty":-0.612655,"median":-0.49689,"eighty":-0.271352,"marketCap":13346706},{"date":"2025-06-06","current":-0.549972,"twenty":-0.608927,"median":-0.497673,"eighty":-0.281282,"marketCap":13501264},{"date":"2025-06-13","current":-0.597709,"twenty":-0.608927,"median":-0.503297,"eighty":-0.294785,"marketCap":14673160},{"date":"2025-06-20","current":-0.557862,"twenty":-0.607995,"median":-0.509511,"eighty":-0.332562,"marketCap":13694949},{"date":"2025-06-27","current":-0.542591,"twenty":-0.603956,"median":-0.515396,"eighty":-0.428478,"marketCap":13320078},{"date":"2025-07-03","current":-0.516978,"twenty":-0.602714,"median":-0.515103,"eighty":-0.429732,"marketCap":12691292},{"date":"2025-07-11","current":-0.572913,"twenty":-0.599701,"median":-0.516978,"eighty":-0.432869,"marketCap":14064436},{"date":"2025-07-18","current":-0.535431,"twenty":-0.597709,"median":-0.518414,"eighty":-0.439456,"marketCap":13144307},{"date":"2025-07-25","current":-0.587857,"twenty":-0.5965,"median":-0.521601,"eighty":-0.450482,"marketCap":14431313},{"date":"2025-08-01","current":-0.482926,"twenty":-0.587857,"median":-0.520838,"eighty":-0.453589,"marketCap":11855342},{"date":"2025-08-08","current":-0.674088,"twenty":-0.587857,"median":-0.518654,"eighty":-0.453589,"marketCap":12464564},{"date":"2025-08-15","current":-0.837521,"twenty":-0.602714,"median":-0.525504,"eighty":-0.453589,"marketCap":15486597},{"date":"2025-08-22","current":-0.836212,"twenty":-0.615141,"median":-0.534692,"eighty":-0.453589,"marketCap":15462399},{"date":"2025-08-29","current":-0.846681,"twenty":-0.624461,"median":-0.53558,"eighty":-0.454826,"marketCap":15655982},{"date":"2025-09-05","current":-0.898895,"twenty":-0.643102,"median":-0.537471,"eighty":-0.457336,"marketCap":16621475},{"date":"2025-09-12","current":-0.894708,"twenty":-0.675347,"median":-0.537746,"eighty":-0.459434,"marketCap":16544042},{"date":"2025-09-17","current":-1.740473,"twenty":-0.693792,"median":-0.540029,"eighty":-0.459802,"marketCap":32183085}],"updateTime":1758205089621},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548170490","title":"Metavia Inc. Conducted Virtual Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2548170490","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548170490?lang=en_us&edition=fundamental","pubTime":"2025-07-01 04:06","pubTimestamp":1751313984,"startTime":"0","endTime":"0","summary":"Metavia Inc. held a virtual annual meeting of stockholders on June 30, 2025. During the meeting, stockholders voted to elect Mark A. Glickman and Michael Salsbury as Class III directors. The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, stockholders approved the issuance of shares of common stock in connection with a private placement to Dong-A Socio Holdings Co., Ltd. Furthermore, authorization was granted for one or more adjournments of the meeting to solicit additional proxies if needed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL9n4v3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2545486451","title":"MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2545486451","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545486451?lang=en_us&edition=fundamental","pubTime":"2025-06-21 21:00","pubTimestamp":1750510819,"startTime":"0","endTime":"0","summary":"MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session. Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis . The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes online.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250621:nNDL9HFWGp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2541096607","title":"Metavia Inc. CFO Marshall H. Woodworth Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541096607","media":"Reuters","labels":["shareholding","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541096607?lang=en_us&edition=fundamental","pubTime":"2025-06-05 04:01","pubTimestamp":1749067306,"startTime":"0","endTime":"0","summary":"Marshall H. Woodworth, the Chief Financial Officer of Metavia Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9kDcxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Metavia Inc. CFO Marshall H. Woodworth Reports Acquisition of Common Shares","news_tag":"shareholding,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2539038842","title":"Metavia Inc. Faces Nasdaq Delisting Risk Due to Sub-$1 Stock Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2539038842","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539038842?lang=en_us&edition=fundamental","pubTime":"2025-05-31 05:06","pubTimestamp":1748639204,"startTime":"0","endTime":"0","summary":"Metavia Inc. has announced that it received a notice from the Nasdaq Stock Market LLC on May 29, 2025, indicating that the company's common stock has not met the minimum bid price requirement for continued listing on the Nasdaq Capital Market. For the past 30 consecutive business days, Metavia's stock has closed below $1.00 per share, falling short of the requirement outlined in Nasdaq Marketplace Rule 5550. The company has until November 25, 2025, to regain compliance, either by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days or by other measures such as a reverse stock split. If compliance is not achieved, Metavia may pursue additional time but could face delisting from Nasdaq if the issue remains unresolved. The company is actively monitoring its stock price and exploring options to address the deficiency.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDLRnHTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2537935332","title":"Metavia Inc. Unveils Presentation on Innovative Cardiometabolic Therapies Targeting Obesity and MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2537935332","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537935332?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:08","pubTimestamp":1747832923,"startTime":"0","endTime":"0","summary":"MetaVia Inc., a clinical-stage biotech company focused on cardiometabolic diseases, recently presented updates on its pipeline of next-generation therapeutics targeting obesity and MASH. The company's investigational drug, DA-1726, a novel GLP1R/GCGR dual agonist, is currently in Phase 1 trials and has shown promising results with significant weight loss and reductions in fasted glucose levels. Additionally, DA-1241, targeting MASH, has met its Phase 2a primary endpoint, demonstrating direct hepatic effects and a strong safety profile. MetaVia continues to explore further studies and regulatory interactions for these treatments. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL2lLtmb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2537623689","title":"Dong-A ST Co., Ltd Acquires Common Shares of Metavia Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2537623689","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537623689?lang=en_us&edition=fundamental","pubTime":"2025-05-21 04:17","pubTimestamp":1747772238,"startTime":"0","endTime":"0","summary":"Dong-A ST Co., Ltd, a beneficial owner, reported an acquisition of common shares of Metavia Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL8h4Ngl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2536406636","title":"MetaVia Is Maintained at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2536406636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536406636?lang=en_us&edition=fundamental","pubTime":"2025-05-20 00:09","pubTimestamp":1747670940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2025 12:09 ET (16:09 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2535557883","title":"MetaVia Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535557883","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535557883?lang=en_us&edition=fundamental","pubTime":"2025-05-15 05:07","pubTimestamp":1747256864,"startTime":"0","endTime":"0","summary":"MetaVia Inc reports results for the quarter ended March 31 - Earnings SummaryMetaVia Inc MTVA.OQ reported a quarterly adjusted loss of 36 cents per share for the quarter ended March 31, higher than th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nL8N3RM2TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2535000798","title":"MetaVia Q1 EPS $(0.36) Beats $(0.51) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535000798","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535000798?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:38","pubTimestamp":1747255134,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.51) by 29.41 percent. This is a 72.73 percent increase over losses of $(1.32) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421823/metavia-q1-eps-0-36-beats-0-51-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2535002074","title":"Metavia Inc. Reports Q1 2025 Results: Net Loss Narrows to $3.7 Million, EPS Improves to $0.36 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2535002074","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535002074?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:07","pubTimestamp":1747253267,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL13dCC7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2535244710","title":"MetaVia Inc. Announces $10 Million At-The-Market Private Placement to Fund Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2535244710","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535244710?lang=en_us&edition=fundamental","pubTime":"2025-05-14 21:04","pubTimestamp":1747227867,"startTime":"0","endTime":"0","summary":"MetaVia Inc., a clinical-stage biotechnology company focused on cardiometabolic diseases, has announced a $10.0 million private placement priced at-the-market under Nasdaq rules. The offering includes the purchase of 9,479,345 shares of common stock at $0.71 per share, along with 4,605,162 pre-funded warrants priced at $0.709 each. The pre-funded warrants come with an exercise price of $0.001 per warrant and are contingent on receiving stockholder approval for the underlying shares. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for this offering. MetaVia plans to use the net proceeds for working capital and corporate purposes, including the clinical development of DA-1726 for obesity treatment. The closing of the private placement is anticipated on or about May 12, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL4sfZnD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2534485955","title":"BRIEF-Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2534485955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534485955?lang=en_us&edition=fundamental","pubTime":"2025-05-09 20:02","pubTimestamp":1746792135,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 9 (Reuters) - MetaVia Inc MTVA.O:METAVIA ANNOUNCES $10.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUAC4LR7X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2533538347","title":"MetaVia Inc  expected to post a loss of 60 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533538347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533538347?lang=en_us&edition=fundamental","pubTime":"2025-05-05 22:11","pubTimestamp":1746454269,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of60cents a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD1IW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0},{"id":"2529301664","title":"BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2529301664","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529301664?lang=en_us&edition=fundamental","pubTime":"2025-04-22 20:33","pubTimestamp":1745325188,"startTime":"0","endTime":"0","summary":"BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA6ZJ01N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}